FDA Approves Lazcluze With Rybrevant for Non-Small Cell Lung Cancer

The FDA has approved lazertinib (Lazcluze, Janssen Biotech) in combination with amivantamab-vmjw (Rybrevant, ...

AUGUST 20, 2024